MassDevice Q&A: Covidien medical devices president José Almeida

January 11, 2010 by Brad Perriello

Covidien's medical devices division president on reviving the company after its spinout from Tyco Healthcare and how it turned around in a down economy.

MassDevice Q&A: Covidien medical devices president Joe Almeida

José Almeida knows what it takes to succeed. The native of Brazil, a mechanical engineer by training, put down roots in the U.S. 20 years ago and never looked back.

Since then he's worked his way up the corporate ladder at firms including Acufex Microsurgical, Johnson & Johnson (NYSE:JNJ), Greatbatch Technologies and Tyco Healthcare. When the latter spun out into Covidien in late June, 2007, Almeida had been in his current role for a year already after spending the better part of 12 years with the company.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Comments

Features

The special sauce in contract research organization Ora Inc.'s recipe for ophthalmology trials is the eye care practice its founder started 30 years ago.

Animal rights advocacy group PETA holds a tiny stake in several medtech companies, taking frequent advantage of its shareholder rights to push changes in the way device makers experiment on animals.

AliveCor's interim-ish CEO Euan Thomson talks about the data-driven future, why he jumped ship at Accuray and how to navigate the intersection between the tempered medical device world and the wanton nimbleness of Silicon Valley.

Medtronic executive Dr. Stephen Oesterle thinks Google will be a force to be reckoned with in the medical technology space in coming years.

Roger Pontz, 1 of the first recipients of Second Sight Medical's Argus II 'bionic eye,' tells MassDevice.com about how it's changed his life.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp